CD3-HAC specifically binds to PD-L1-positive tumor cells to attenuate the impact of PD-1/PD-L1 on T cells exposed to MDA-MB-231, leading to enhanced T cell activation and stimulated lymphocyte-mediated lysis both in vitro and in vivo (223). The gene discussed is CD274; the disease is neoplasm.